ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 682

Misalignment Between Physician and Patient Satisfaction with Current Psoriatic Arthritis Treatment

Daniel E. Furst1, Emma Sullivan2, James Pike3, James Piercy4, Jacqueline Palmer5 and Vivian Herrera5, 1Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Adelphi Real World, Manchester, United Kingdom, 3Statistics, Adelphi Real World, Macclesfield, United Kingdom, 4Adelphi Real World, Macclesfield, United Kingdom, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Clinical practice, patient outcomes, Psoriatic arthritis, severity and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Psoriatic Arthritis (PsA) is a chronic immune related condition affecting the joints and commonly occurs alongside psoriasis. Well-established physician patient relationships are instrumental to obtaining the best patient outcomes.

The objective of this analysis was to assess the extent of misalignment between physicians and their PsA patients in terms of satisfaction with current control of their PsA. We then compared aligned and misaligned patients in terms of demographic factors, drug treatments, symptoms, comorbid conditions and patient reported outcomes.

Methods:

Data were drawn from the Adelphi 2011 and 2014 Rheumatology Disease Specific Programmes surveys of rheumatologists and their PsA patients in the USA. Rheumatologists with responsibility for managing PsA patients were recruited and provided patient demographics, clinical details, comorbidities and satisfaction with PsA treatment. Patients reported their satisfaction, and completed the Work Productivity Activity Impairment (WPAI) questionnaire, and alternative HAQ-DI (excluding aids and devices) questionnaire.

Levels of satisfaction agreement between physician and patient responses were constructed and compared: aligned (physician and patient both satisfied, or physician and patient both dissatisfied with PsA treatment) and misaligned (physician and patient reported satisfaction with PsA treatment was different). Descriptive statistics including means and frequencies were derived.

Results:

From 305 paired rheumatologists and PsA patient records, 233 (76.4%) were ‘aligned’, consisting of 65.3% with both physician and patient satisfied, and 11.1% with both dissatisfied.72 (23.6%) cases were ‘misaligned’. The aligned and misaligned groups were similar in terms of age (mean 50.0, 49.8) and sex (% female: 44.6, 45.8). However, the aligned group had longer time since diagnosis compared with misaligned (mean years: 6.4, 5.2) and were more likely to receive biologic DMARD (bDMARD) therapy (% receiving bDMARD: 62.9, 49.3).

The misaligned group tended to be more symptomatic, having higher TJC (mean 5.6 vs. 2.9), SJC (mean: 3.7, 1.9), higher BSA (>3% BSA affected: 64.2% vs. 55.1%), higher number of PsA symptoms (mean: 6.8, 4.9). The most common concomitant conditions were hypertension (28.9%), elevated cholesterol (20.0%), depression (14.1%), obesity (13.8%) and anxiety (10.8%). A greater proportion of misaligned patients had depression (20.8% vs. 12.0%) and anxiety (15.3% vs. 9.4%). As reported in the WPAI, the misaligned were also more impaired in their overall work (mean 38.7% vs. 21.4%), while at work i.e. presenteeism (mean 36.2% vs. 16.5%) and in their daily activities (mean 38.7% vs. 22.3%). Additionally they had higher disability (mean alternative HAQ-DI score: 0.563 vs. 0.369).

Conclusion:

Misalignment between rheumatologists and their PsA patients in satisfaction with PsA treatment exists in almost a quarter of cases. In cases of misalignment, disease severity and patient reported outcomes were worse. The findings suggest that a greater degree of alignment might result in improved outcomes, although further research would be required to verify this hypothesis.


Disclosure: D. E. Furst, Gilead, 2,GlaxoSmithKline, 2,NIH, 2,Novartis Pharmaceutical Corporation, 2,Pfizer Inc, 2,Roche Pharmaceuticals, 2,Genentech and Biogen IDEC Inc., 2,UCB, 2,Abbvie, 5,Actelion Pharmaceuticals US, 5,Amgen, 5,Bristol-Myers Squibb, 5,Cytori, 5,Janssen Pharmaceutica Product, L.P., 5,Gilead, 5,GlaxoSmithKline, 5,NIH, 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,Genentech and Biogen IDEC Inc., 5,UCB, 5,Abbvie, 8,Actelion Pharmaceuticals US, 8,Bristol-Myers Squibb, 2,Amgen, 2,Actelion Pharmaceuticals US, 2,Abbvie, 2,UCB, 8; E. Sullivan, Adelphi Real World, 3,Novartis Pharmaceutical Corporation, 9; J. Pike, Adelphi Real World, 3,Novartis Pharmaceutical Corporation, 9; J. Piercy, Adelphi Real World, 3,Novartis Pharmaceutical Corporation, 9; J. Palmer, Novartis Pharmaceutical Corporation, 3; V. Herrera, Novartis Pharmaceutical Corporation, 3,Novartis Pharmaceutical Corporation, 1.

To cite this abstract in AMA style:

Furst DE, Sullivan E, Pike J, Piercy J, Palmer J, Herrera V. Misalignment Between Physician and Patient Satisfaction with Current Psoriatic Arthritis Treatment [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/misalignment-between-physician-and-patient-satisfaction-with-current-psoriatic-arthritis-treatment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/misalignment-between-physician-and-patient-satisfaction-with-current-psoriatic-arthritis-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology